Financial Analysis: Motus GI vs. InspireMD

Comparing the performance and potential of two small-cap medical companies

Published on Feb. 8, 2026

Got story updates? Submit your updates here. ›

Motus GI (NASDAQ:MOTS) and InspireMD (NYSE:NSPR) are both small-cap medical companies, but which one is the better investment? This analysis compares the two firms across key metrics like earnings, risk, profitability, valuation, analyst recommendations, dividends, and institutional ownership to determine which stock is the superior choice.

Why it matters

Understanding the relative strengths and weaknesses of Motus GI and InspireMD can help investors make more informed decisions about allocating their capital in the small-cap medical device sector. This analysis provides a comprehensive look at the two companies to identify which one may be poised for greater long-term success.

The details

The analysis examines factors like revenue, earnings per share, valuation, institutional ownership, insider ownership, analyst recommendations, profit margins, return on equity, and return on assets. It finds that InspireMD has stronger consensus ratings from analysts, higher potential upside, and better profitability metrics compared to Motus GI. However, Motus GI has lower stock price volatility.

  • The analysis was published on February 8, 2026.

The players

Motus GI

A medical technology company that develops the Pure-Vu system to facilitate gastrointestinal tract cleansing during colonoscopies and upper endoscopies.

InspireMD

A medical device company that focuses on the development and commercialization of its MicroNet stent platform technology for treating vascular and coronary diseases.

Got photos? Submit your photos here. ›

The takeaway

This analysis highlights the key differences between Motus GI and InspireMD, with InspireMD emerging as the more favorable investment option based on factors like analyst sentiment, profitability, and valuation. However, Motus GI's lower volatility may appeal to more risk-averse investors. Ultimately, investors should carefully weigh the strengths and weaknesses of each company to determine which best aligns with their investment goals and risk tolerance.